Alliancebernstein L.P. Lowers Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Alliancebernstein L.P. lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 10.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 174,020 shares of the biopharmaceutical company's stock after selling 19,550 shares during the quarter. Alliancebernstein L.P. owned 0.11% of TG Therapeutics worth $5,238,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. HighTower Advisors LLC grew its holdings in shares of TG Therapeutics by 19.6% during the 3rd quarter. HighTower Advisors LLC now owns 12,526 shares of the biopharmaceutical company's stock valued at $294,000 after purchasing an additional 2,053 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of TG Therapeutics by 12.7% during the third quarter. Wellington Management Group LLP now owns 73,320 shares of the biopharmaceutical company's stock valued at $1,715,000 after purchasing an additional 8,249 shares in the last quarter. Barclays PLC grew its holdings in shares of TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in shares of TG Therapeutics in the third quarter valued at approximately $1,039,000. Finally, Synovus Financial Corp acquired a new stake in TG Therapeutics during the 3rd quarter worth approximately $465,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock traded up $0.62 on Tuesday, reaching $39.03. 1,600,072 shares of the company traded hands, compared to its average volume of 3,110,681. The company has a 50 day moving average of $35.98 and a 200 day moving average of $31.60. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32. The firm has a market capitalization of $6.13 billion, a PE ratio of -390.26 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Equities analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.